A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, ...

Panelists discuss how real-world data from the San Antonio Breast Cancer Symposium demonstrated that elacestrant's ...

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a ...

Panelists discuss strategies for medication adherence and patient education, emphasizing the importance of proactive communication and support from the entire health care team.

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to ...

The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.

Patients with stage III and high-risk stage II colon cancer who participated in an exercise program saw improved disease-free ...

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with ...

NIVOPOSTOP trial data demonstrate a reduction in the risk of recurrence or death with adjuvant nivolumab combined with ...

Patients with stage III resected colon cancer had lower risk of death with less inflammatory diets and more regular physical ...

Patients with HR-positive, HER2-negative metastatic breast cancer should be consistently tested for ESR1 mutations to inform ...

The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.